Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alenia is a brand name used internationally for different pharmaceutical products depending on the country. In Brazil, Alenia contains budesonide and formoterol fumarate dihydrate, making it a combination inhaler used primarily for the management of asthma and chronic obstructive pulmonary disease (COPD). Budesonide is an inhaled corticosteroid that reduces inflammation in the airways, while formoterol is a long-acting beta2-adrenergic agonist (LABA) that relaxes bronchial smooth muscle to improve airflow. In Bangladesh, Alenia contains esomeprazole, which is a proton pump inhibitor used to reduce stomach acid production in conditions such as gastroesophageal reflux disease (GERD). The specific mechanism of action depends on the formulation: - For budesonide/formoterol: anti-inflammatory effects via glucocorticoid receptor activation and bronchodilation via beta2-adrenoceptor agonism. - For esomeprazole: inhibition of gastric H+/K+ ATPase enzyme system.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alenia.